A Potential Drug Target and Biomarker: CNOT6L (CNO6L_HUMAN) (G246175)

Target Name: CNOT6L

NCBI ID: G246175

CNOT6L

A Potential Drug Target and Biomarker: CNOT6L (CNO6L_HUMAN)

CNO6L_HUMAN, or nicotinamide riboside (NR) 6-carboxylate, is a 6-carboxylate derivative of the amino acid nicotinamide riboside (NR). As a novel small molecule drug, CNOT6L has been shown to possess potential therapeutic benefits in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will explore the potential drug target and biomarker properties of CNOT6L and its implications for human health.

CNO6L_HUMAN as a Drug Target

CNO6L_HUMAN has been identified as a potential drug target due to its unique structural features and its ability to interact with various cellular components. One of its most significant advantages is its ability to cross the blood-brain barrier (BBB), which is a challenge for many drugs that attempt to reach therapeutic concentrations in the central nervous system (CNS). The CBB is designed to prevent the entry of foreign particles, including drugs, into the brain, but it can be easily bypassed by molecules that have a weak charge or are able to conform to the shape of the blood vessels. CNOT6L's ability to cross the BBB suggests that it may have unique benefits for treating diseases in the CNS, such as stroke, Alzheimer's disease, and Parkinson's disease.

In addition to its potential therapeutic benefits, CNOT6L has also been shown to interact with several key cellular components that are involved in various diseases, including neurodegenerative disorders. For example, studies have shown that CNOT6L can interact with the neurotransmitter dopamine, which is involved in the treatment of many neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease. By modulating the levels of dopamine in the brain, CNOT6L may have therapeutic benefits for these disorders.

CNO6L_HUMAN as a Biomarker

CNO6L_HUMAN has also been shown to serve as a potential biomarker for several diseases, including cancer. The ability of CNOT6L to interact with DNA and to promote apoptosis (programmed cell death) in cancer cells makes it an attractive candidate for use as a therapeutic agent. By inhibiting the activity of DNA-binding proteins, CNOT6L may be able to inhibit the growth and spread of cancer cells. In addition, the anti-inflammatory effects of CNOT6L have been shown to be beneficial for cancer patients, as it has been shown to reduce inflammation in the body, which is often associated with the development and progression of cancer.

CNO6L_HUMAN as a Therapeutic

The potential therapeutic benefits of CNOT6L are vast and continue to be explored by researchers. One of the most promising potential uses for CNOT6L is its potential to treat stroke, which is a leading cause of death and disability worldwide. stroke is a complex disease that is often treated with a combination of medications that aim to reduce the risk of recurrence and improve symptoms. However, the majority of these treatments are limited in their effectiveness and can have significant side effects.

CNO6L has been shown to have potential benefits as a stroke treatment due to its ability to promote the production of new blood vessels, which can help to improve blood flow to the brain and reduce the risk of recurrence. In addition, CNOT6L has also been shown to reduce the amount of damage caused by stroke in the brain by promoting the production of repair proteins.

Another potential therapeutic use of CNOT6L is its ability to treat neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive loss of brain cells and can have a significant impact on an individual's quality of life. CNOT6L has been shown to have potential benefits in treating these disorders by promoting the production of new neurons and reducing inflammation in the brain.

Conclusion

In conclusion, CNOT6L_HUMAN is a novel small molecule drug that has potential therapeutic benefits in a variety of diseases, including stroke, neurodegenerative disorders, and cancer. Its ability to cross the blood-brain barrier and interact with cellular components makes it an attractive candidate for use as a therapeutic agent. Further research is needed to fully understand the potential benefits and risks of CNOT6L, as well as its potential as a biomarker. As research continues, the potential of CNOT6L as a drug target and biomarker will continue to be explored, and its use in human health will be greatly expanded.

Protein Name: CCR4-NOT Transcription Complex Subunit 6 Like

Functions: Has 3'-5' poly(A) exoribonuclease activity for synthetic poly(A) RNA substrate. Catalytic component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation. Additional complex functions may be a consequence of its influence on mRNA expression. May be involved in the deadenylation-dependent degradation of mRNAs through the 3'-UTR AU-rich element-mediated mechanism. Involved in deadenylation-dependent degradation of CDKN1B mRNA. Its mRNA deadenylase activity can be inhibited by TOB1. Mediates cell proliferation and cell survival and prevents cellular senescence

The "CNOT6L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNOT6L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets